UARK 99-016, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Multiple Myeloma and Poor Hematopoietic Stem Cell Reserve
Recently, laboratory research found that thalidomide can inhibit the formation of new blood
vessels that are necessary for the growth and spread of cancer. In order to grow and
increase in size, tumors require new blood vessels to supply them with the necessary blood
to grow. If we can prevent these new blood vessels feeding the tumor from being formed by
using thalidomide we might slow or stop the growth of the tumor. This concept is called
"anti-angiogenesis". It is hoped that thalidomide will slow or stop the growth myeloma.
However, it cannot be guaranteed that you will benefit if you take part in this study. The
treatment you receive may even be harmful.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the effectiveness of combination treatment with Thalidomide and Pamidronate in patients with refractory myeloma and poor hematopoietic stem cell reserve. Effectiveness will be based on the estimate of the objective response rate (CR + PR).
Athanasios Fassas, M.D.
University of Arkansas
United States: Food and Drug Administration
|University of Arkansas for Medical Sciences/MIRT||Little Rock, Arkansas 72205|